Epigenetic therapies for chemoresensitization of epithelial ovarian cancer

Daniela E. Matei*, Kenneth P. Nephew

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

81 Scopus citations


Epigenetic drugs have been shown to enhance gene expression and drug sensitivity in ovarian cancer cell lines and animal models. Based on promising preclinical studies, DNA methylation inhibitors in combination with existing chemotherapeutic agents have the potential for overcoming acquired drug resistance, laying the foundation for this specific class of epigenetic drug in ovarian cancer clinical trials. The recent completion of phase I trials of decitabine has yielded important information on dosing schedules and biological endpoints for evaluating patient responses. In addition, epigenetic drug effects on pharmacodyamic targets are beginning to emerge, and predictive epigenetic biomarkers and next generation epigenome therapeutics are being developed for application in clinical settings for ovarian cancer patients.

Original languageEnglish (US)
Pages (from-to)195-201
Number of pages7
JournalGynecologic oncology
Issue number2
StatePublished - Feb 2010


  • Chemosensitization
  • Epigenetics
  • HDAC inhibitor
  • Ovarian cancer
  • Platinum resistance

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology


Dive into the research topics of 'Epigenetic therapies for chemoresensitization of epithelial ovarian cancer'. Together they form a unique fingerprint.

Cite this